Navigation Links
Advanced Cell Diagnostics Initiates Agreement to Study Biomarkers for Cancer Immunotherapy
Date:3/4/2013

HAYWARD, Calif., March 4th, 2013 /PRNewswire/ -- Advanced Cell Diagnostics, Inc. (ACD) announced today that they have entered into an agreement with The Johns Hopkins University on behalf of its Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins to use ACD's proprietary RNAscope® technology platform to validate novel biomarkers and drug targets for cancer immunotherapy.

Cancer immunotherapy, which aims to mobilize a patient's immune system to fight cancer, has been gaining momentum recently with the FDA approval of anti-CTLA-4 therapy for melanoma and with the recent impressive and durable remissions produced by targeting PD1 in multiple solid tumors in early-phase clinical trials led by Johns Hopkins investigators. With many additional immune modulatory molecules identified for targeting that play major roles in specific subsets of cancer, it will be critical to develop standardized biomarkers to guide the application of the most effective immune therapies on a patient by patient basis.

Targeting the immune checkpoints that are often suppressed in many cancers has demonstrated tremendous potential.  However, to identify biomarkers useful for guiding therapy, conventional approaches to biomarker analysis have proven inadequate, leading to conflicting results.

"The complex interplay between cancer cells and the immune system in the tumor microenvironment matches perfectly with RNAscope's capability of single molecule sensitivity and single cell resolution, which can help pinpoint which cell is talking to which other cell," said Dr. Yuling Luo , Founder, President and CEO of ACD.  Dr. Luo added, "That knowledge will be essential for selecting optimal targets for drug development and predicting which patient will benefit from it. We feel extremely fortunate to be able to provide such a tool to the pioneers in this emerging and exciting field."

About RNAscope
RNAscope technology is the first automated multiplex RNA in situ hybridization platform capable of detecting and quantifying biomarkers with single‐molecule sensitivity. Traditionally, RNA biomarkers are analyzed by "grind‐and‐bind" assays such as RT‐PCR in homogenized tissue, which loses information about cellular context and disease microenvironment that is critical for clinical interpretation. RNAscope provides single‐cell gene expression information within the context of intact tissue, enabling both molecular and histopathological analysis on a platform that is compatible with routine clinical specimens and standard clinical laboratory workflow. Unlike IHC antibodies which are available for only a small fraction of the human proteome and not suitable for the emerging class of non‐coding RNAs, RNAscope assays can be developed and validated in two weeks for virtually any gene in any genome. Currently, ACD offers RNAscope‐based products and services worldwide to scientists in a broad range of research areas from basic research to companion diagnostics for personalized medicine. Customers include world‐renowned academic institutions and all major pharmaceutical/biotech companies.

About Advanced Cell Diagnostics
Advanced Cell Diagnostics, Inc. (ACD) is a leader in the emerging field of molecular pathology, developing cell and tissue‐based diagnostic tests for personalized medicine. The company's products and services are based on its proprietary RNAscope® technology, the first automated multiplex chromogenic and fluorescent in situ hybridization platform capable of detecting and quantifying RNA biomarkers in situ at single‐molecule sensitivity. RNAscope assays are currently used by hundreds of customers, including all of the global top 10 pharmaceutical companies, world leading academic institutions and many cutting edge biotechnology companies to validate biomarkers for the management of cancer and other diseases.  ACD's industrial partnerships provide the foundation for ACD to develop companion diagnostic tests in conjunction with partners' targeted therapeutics. ACD also pursues internal programs to develop and commercialize proprietary diagnostic tests in cancer management. Learn more about ACD and RNAscope technology at www.acdbio.com.

Contact:
Steve Chen , Ph.D.
Chief Operating Officer
(510) 259-9802
schen@acdbio.com


'/>"/>
SOURCE Advanced Cell Diagnostics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Industry Thought Leader to Present Transformational Opportunities for Industry Adoption of Advanced Analytics at 2013 HIMSS Annual Conference & Exhibition
2. SPIE Advanced Lithography will Bring Industry Focus to Next-generation Tools and Systems
3. Rigaku publishes new WDXRF Application: Determination of Metals in Copper Concentrate by Advanced Correction Method for Fused Beads
4. Advanced Cell Diagnostics Appoints Evangeline Gonzalez as Chief Commercial Officer
5. New Advanced High End Brix Refractometer
6. INRS acquires a groundbreaking advanced imaging infrastructure
7. GIN Introduces Advanced Robotics and Dispensing Technnology at SLAS 2013 in Orlando, FL
8. Nanonex Delivered Advanced Nanoimprint Tool NX-B200 to Swinburne University of Technology, Australia
9. University of Pennsylvania Purchases Nanonex Advanced Nanoimprint Tool NX-2600 BA
10. Advanced Polymer Trading to Exhibit at ArabPlast 2013 in Dubai
11. Dallas-Fort Worth Fertility Associates Celebrates First Birth in North Texas from Advanced Trophectoderm Biopsy Screening Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... Prussia, PA (PRWEB) , ... February 09, 2016 , ... ... Development, Europe. Based in Paris, he will focus on acquiring new accounts and ... being met. , “Fred brings to our European clients more than ...
(Date:2/9/2016)... CA (PRWEB) , ... February 09, 2016 , ... ... strategic changes over the years and Open Access publishing is one of the ... With its 700+ open access journals and 3000+ International Conferences ...
(Date:2/9/2016)... Feb. 9, 2016  DNAtrix, a clinical ... cancer, announced that its lead product, DNX-2401, ... as an orphan medicinal product for the ... of glioma, strikes approximately 25,000 people a ... http://photos.prnewswire.com/prnh/20160208/330986LOGO --> ...
(Date:2/9/2016)... and LONDON , February 9, 2016 /PRNewswire/ ... tech replace paper and protect IP   ... laboratory notebook (ELN) will be rolled out in ... and development (R&D) and protect valuable IP. Users will be ... a specific researcher or experiment as part of the application, ...
Breaking Biology Technology:
(Date:1/20/2016)... Jan. 20, 2016   MedNet Solutions , an ... spectrum of clinical research, is pleased to announce the ... achievements are the result of the company,s laser focus ... eClinical , it,s comprehensive, easy-to-use and highly affordable ... --> Key MedNet growth achievements in 2015 include: ...
(Date:1/13/2016)... 2016 --> ... market report titled - Biometric Sensors Market - Global Industry ... 2023. According to the report, the global biometric sensors market was valued ... reach US$1,625.8 mn by 2023, expanding at a CAGR ... volume, the biometric sensors market is expected to reach ...
(Date:1/8/2016)... and MANCHESTER, United Kingdom , Jan. 8, ... of innovative sensor-based diagnostic products, today announced the closing of ... and existing investors.  Proceeds from the financing will be used ... a hand-held device for detecting early-stage pressure ulcers. ... after receiving CE Mark approval. The device,s introduction ...
Breaking Biology News(10 mins):